Trial in Low Grade Glioma Patients: Wait or Treat

Inclusion Criteria

• •Histologically WHO grade II (diffuse) or III (anaplastic) astrocytoma, IDHmt without 1p/19q co-deletion (local diagnosis)
• •Time since diagnostic surgery or first resection ≤ 6 months
• •No need for immediate radiotherapy followed by chemotherapy
• •Having seizures only, without functional deficits due to the tumor (but the presence of functional deficits due to the resection is allowed)
• •Patients for whom by local judgment an active surveillance policy is a realistic management alternative
• •The patient is at least 18 years of age on day of signing informed consent
• •WHO PS 0-2
• •Adequate hematological, renal, and hepatic function, as follows:
• •* Absolute neutrophil count ≥ 1.5 x 10\*9/L
• •* Platelets ≥ 100 × 10\*9/L
• •* Serum creatinine ≤ 1.5 times upper limit of laboratory normal (ULN)
• •* Total serum bilirubin ≤ 1.5 × ULN
• •* AST and ALT ≤ 2.5 × ULN
• •* Alkaline phosphatase of ≤ 2.5 × ULN
• •Presence of at least one paraffin block from the initial diagnosis for pathology review and translational research. If a representative formalin-fixed, paraffin-embedded (FFPE) block is not available, the collection of optimally 36, minimally 24 x 5 µm, unstained slides is required.
• •At the time of randomization presence only of a non-enhancing tumor on T1 weighted contrast enhanced MR images; some faint non-nodular enhancement or enhancement that can be ascribed to the surgical resection or peri-operative ischemia is allowed. Preoperative enhancement is allowed provided this area is resected as shown on postoperative imaging
• •Ability to take oral medication
• •Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test done within 72 hours prior to randomization
• •Patients of childbearing / reproductive potential must agree to use adequate birth control measures, as defined by the investigator, during RT and TMZ treatment and for at least 6 months after the last TMZ cycle. A highly effective method of birth control is defined as those which result in low failure rate (i.e., less than 1 percent per year) when used consistently and correctly
• •Women who are breast feeding must agree to discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment
• •Male patients should be advised not to father a child and not to donate sperm up to 6 months after receiving the last dose of TMZ, and to seek advice on cryoconservation of sperm prior to treatment start
• •Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments
• •Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations